Mersana Therapeutics, Inc. (MRSN): Price and Financial Metrics

Mersana Therapeutics, Inc. (MRSN): $8.45

-0.02 (-0.24%)

POWR Rating

Component Grades













Add MRSN to Watchlist
Sign Up

Industry: Biotech


of 503

in industry


  • Momentum is the dimension where MRSN ranks best; there it ranks ahead of 47.4% of US stocks.
  • MRSN's strongest trending metric is Growth; it's been moving down over the last 52 weeks.
  • MRSN ranks lowest in Growth; there it ranks in the 4th percentile.

MRSN Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for MRSN is 0 -- better than merely 6.23% of US stocks.
  • MRSN's price/sales ratio is 14,336; that's higher than the P/S ratio of 99.74% of US stocks.
  • As for revenue growth, note that MRSN's revenue has grown -97.4% over the past 12 months; that beats the revenue growth of merely 0.92% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Mersana Therapeutics Inc, a group of peers worth examining would be CALT, TFFP, VNRX, CVM, and ARDS.
  • MRSN's SEC filings can be seen here. And to visit Mersana Therapeutics Inc's official web site, go to

MRSN Valuation Summary

  • MRSN's EV/EBIT ratio is -6.3; this is 121.5% lower than that of the median Healthcare stock.
  • Over the past 51 months, MRSN's price/sales ratio has gone up 22705.9.
  • Over the past 51 months, MRSN's price/sales ratio has gone up 22705.9.

Below are key valuation metrics over time for MRSN.

Stock Date P/S P/B P/E EV/EBIT
MRSN 2021-08-31 22718.2 5.1 -7.9 -6.3
MRSN 2021-08-30 22279.5 5.0 -7.7 -6.1
MRSN 2021-08-27 21218.2 4.8 -7.4 -5.7
MRSN 2021-08-26 19213.6 4.3 -6.7 -5.0
MRSN 2021-08-25 19277.3 4.3 -6.7 -5.1
MRSN 2021-08-24 18804.5 4.2 -6.5 -4.9

MRSN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MRSN has a Quality Grade of D, ranking ahead of 23.99% of graded US stocks.
  • Service Unavailable
  • ARNA, EYEG, and AGTC are the stocks whose asset turnover ratios are most correlated with MRSN.

The table below shows MRSN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.000 1 -19.265
2021-03-31 0.003 1 -11.244
2020-12-31 0.003 1 -4.878
2020-09-30 0.004 1 -3.132
2020-06-30 0.011 1 -2.130
2020-03-31 0.009 1 -2.198

MRSN Price Target

For more insight on analysts targets of MRSN, see our MRSN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $26.67 Average Broker Recommendation 1.29 (Strong Buy)

MRSN Stock Price Chart Interactive Chart >

Price chart for MRSN

MRSN Price/Volume Stats

Current price $8.45 52-week high $29.09
Prev. close $8.47 52-week low $8.16
Day low $8.35 Volume 100,102
Day high $8.61 Avg. volume 797,156
50-day MA $10.57 Dividend yield N/A
200-day MA $14.77 Market Cap 606.39M

Mersana Therapeutics, Inc. (MRSN) Company Bio

Mersana Therapeutics, Inc. is a biotechnology company that discovers, engineers, and develops antibody drug conjugates to cure various cancers. The company develops immune conjugate therapies to create drugs that enhance patients’ lives. It offers XMT-1522, a drug therapy for tumor models that express relatively low amounts of the HER2 protein; and human anti-HER2 antibody used in XMT-1522. Mersana Therapeutics, Inc. has strategic alliances with Takeda Pharmaceutical Company Limited; Merck Serono; and Asana BioSciences. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.

MRSN Latest News Stream

Event/Time News Detail
Loading, please wait...

MRSN Latest Social Stream

Loading social stream, please wait...

View Full MRSN Social Stream

Latest MRSN News From Around the Web

Below are the latest news stories about Mersana Therapeutics Inc that investors may wish to consider to help them evaluate MRSN as an investment opportunity.

Hedge Funds Are Betting On Mersana Therapeutics, Inc. (MRSN)

In this article we will analyze whether Mersana Therapeutics, Inc. (NASDAQ:MRSN) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There’s no better way to get these firms’ immense resources and analytical capabilities working for us than to follow their lead […]

Yahoo | October 18, 2021

Mersana Highlights New Preclinical Data For XMT-2056 Cancer Settings

Mersana Therapeutics Inc (NASDAQ: MRSN) has announced new preclinical data of XMT-2056. Data were presented at the AACR-NCI-EORTC Virtual International Conference. XMT-2056 is an Immunosynthen STING-agonist ADC candidate, targeting an epitope of human epidermal growth factor receptor 2 (HER2). Previously, across multiple targets and models, Immunosynthen ADCs stimulated the innate immune system in a targeted manner in both tumor cells and tumor-resident myeloid cells. In new head-to-head preclin

Yahoo | October 8, 2021

Mersana Therapeutics Announces Target and Presents New Preclinical Data for XMT-2056, First Immunosynthen STING-Agonist ADC, at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Preclinical data demonstrate that XMT-2056 activates the STING pathway in a target-dependent manner in both tumor cells and tumor-resident immune cells and is significantly more efficacious in head-to-head studies than trastuzumab-TLR7/8 agonist ADC and small-molecule systemically-administered STING agonist benchmarksXMT-2056 targets a novel epitope of HER2 with differentiated binding from trastuzumab and pertuzumab, potentially allowing for broad combinability with approved and investigational

Yahoo | October 7, 2021

Mersana Therapeutics to Announce Target and Present New Preclinical Data for XMT-2056 at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

CAMBRIDGE, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will disclose the target and present new preclinical data for XMT-2056, its first Immunosynthen STING-agonist ADC candidate, in a plenary session at the upcoming AACR-NCI-EORTC Virtual International

Yahoo | September 30, 2021

Is Mersana Stock a Buy Right Now? This Is What You Need to Know

If you’re after big returns, the biotech sector is your go-to destination, although investors should proceed with caution as instead of mighty gains a portfolio can also dwindle alarmingly if a company in the highly volatile sector fails to deliver the goods. Which is what investors evidently felt after taking in the latest news out of Mersana Therapeutics (MRSN) HQ. On Friday, shares shed about 40% of their value after the company provided a clinical trial update. The company disclosed interim

Yahoo | September 13, 2021

Read More 'MRSN' Stories Here

MRSN Price Returns

1-mo -11.89%
3-mo -28.99%
6-mo -47.25%
1-year -52.77%
3-year 12.82%
5-year N/A
YTD -68.25%
2020 364.40%
2019 40.44%
2018 -75.17%
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9352 seconds.